Thyroid Malignancy: Variants, Pathology, Management, Staging & Follow-up

Overview

1. Papillary Thyroid Carcinoma (PTC)

Pathology

• Branching papillae with fibrovascular stalks covered by cuboidal epithelium
• Ground-glass (Orphan Annie) nuclei - optically clear appearance due to finely dispersed chromatin
• Intranuclear pseudoinclusions and nuclear grooves (cytoplasmic invaginations)
• Psammoma bodies - concentric calcifications in papillary cores; almost never in follicular or medullary carcinomas
• Lymphatic invasion common; blood vessel invasion uncommon in smaller lesions
• Cervical lymph node metastases in up to 50% of cases

• BRAF V600E - most common point mutation (~45% of PTC), activates MAPK pathway, associated with aggressive features and RAI resistance
• RAS mutations - 20-30%, more common in follicular variant PTC; activates both MAPK and PI3K-AKT
• RET/PTC rearrangements - 5-10%, characteristic of radiation-induced PTC; multifocal, more extrathyroidal extension
• TERT promoter mutations - up to 27%, especially co-occurring with BRAF; associated with RAI resistance and high recurrence risk
• PAX8-PPARG - seen in follicular variant PTC

• Classical/conventional
• Follicular variant (encapsulated vs infiltrative) - most common variant; almost totally follicular architecture but PTC nuclear features
• Tall cell variant - aggressive, occurs in older patients
• Columnar cell variant - aggressive
• Diffuse sclerosing variant
• Solid/trabecular variant
• Hobnail variant - high recurrence risk
• Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) - reclassified as non-malignant

2. Follicular Thyroid Carcinoma (FTC)

Pathology

• Minimally invasive - capsular invasion only; very low metastatic risk; <10% die within 10 years
• Widely invasive/angioinvasive - blood vessel invasion; metastases to lung, bone, liver; up to 50% die within 10 years

3. Oncocytic (Hürthle Cell) Carcinoma (OCA)

4. Medullary Thyroid Carcinoma (MTC)

Pathology

• RET proto-oncogene (chromosome 10q11.2) - germline mutations in virtually all hereditary MTC; somatic (acquired) RET mutations in ~50% of sporadic MTC
• Codon C634 mutations are most common in hereditary MTC

• Sporadic (~75%) - unifocal; usually presents 4th-6th decade; up to 50% have palpable neck mass; cervical nodal metastases in >70% with palpable tumor; distant mets (liver, mediastinum, lungs, bone) in 10-15%
• Familial (~25%):
  • MEN 2A (Sipple syndrome) - MTC + pheochromocytoma + primary hyperparathyroidism; codon 634 RET mutation; presents 3rd decade
  • MEN 2B - MTC + pheochromocytoma + marfanoid habitus + mucosal neuromas + intestinal ganglioneuromatosis; codon M918T mutation; most aggressive; presents before 2nd decade
  • Familial MTC - MTC without other MEN features

• Highest risk (MEN 2B, M918T mutation) - prophylactic thyroidectomy within first 6 months of life
• High risk (C634F/G/R/S/W/Y, C609, C611, etc.) - thyroidectomy before age 5 years
• Moderate risk - thyroidectomy timing guided by calcitonin levels/imaging

5. Anaplastic Thyroid Carcinoma (ATC)

Pathology

6. TNM Staging (AJCC 8th Edition)

Primary Tumor (T)

Regional Lymph Nodes (N)

Stage Grouping - Differentiated TC (PTC/FTC/OCA/PDTC)

Additional Risk-Stratification Systems

• MACIS (Mayo Clinic): Score based on Metastasis + Age + Completeness of resection + Invasion + Size. Score <6.0 = 99% 20-year survival
• AMES: Age, Metastases, Extent of tumor, Size - divides into low-risk and high-risk groups
• ATA Dynamic Risk Stratification - assigns response-to-therapy categories after treatment:
  1. Excellent response - no clinical, biochemical, or structural evidence of disease (1-4% recurrence risk)
  2. Biochemical incomplete response - abnormal Tg or rising anti-Tg antibodies, no structural disease (50% achieve NED spontaneously or with Rx)
  3. Structural incomplete response - persistent locoregional or distant disease (mortality up to 50% with distant mets)
  4. Indeterminate response - nonspecific findings (15-20% develop structural disease)

7. Management

Differentiated Thyroid Cancer (PTC, FTC, OCA)

• Thyroid lobectomy - acceptable for low-risk, unilateral DTC 1-4 cm, no ETE, no metastatic disease; recommended for <1 cm DTC (after active surveillance discussion)
• Total thyroidectomy - preferred for (Sabiston, p. 1515):
  • Tumor ≥4 cm
  • Clinically evident nodal metastases
  • Gross extrathyroidal extension
  • Evidence of distant metastatic disease
  • Radiation-induced DTC
  • Familial non-medullary TC
  • Multifocal bilateral DTC
• Active surveillance - an option for small (<1.5 cm) intrathyroidal micropapillary cancers without cervical LN mets, ETE, or proximity to the recurrent laryngeal nerve

• Therapeutic compartment-based dissection for clinically/radiographically evident nodal disease
• Central compartment (level VI ± VII) dissection for ipsilateral central nodal involvement
• Lateral neck dissection (levels II-V) for proven lateral neck metastases
• Prophylactic central neck dissection remains controversial

• Not indicated for T1 tumors ≤2 cm confined to thyroid (no recurrence/survival benefit)
• No benefit demonstrated for larger (>2 cm but <4 cm) low-risk tumors
• Indicated for higher risk patients: larger tumors, aggressive variants, vascular invasion, ETE, large-volume lymph node metastases, older patients
• Low-dose ¹³¹I (1100 MBq / 30 mCi) for remnant ablation; high-dose (up to 5500 MBq / 150 mCi) for adjuvant treatment of residual/metastatic disease
• Requires TSH stimulation (TSH >25 mIU/L) - achieved by either thyroid hormone withdrawal or recombinant human TSH (rhTSH, thyrotropin alfa)
• Preceded by low-iodine diet for 1-2 weeks

• Levothyroxine to suppress TSH - rationale: differentiated TCs express TSH-R and remain responsive to TSH stimulation
• Degree of suppression tailored to risk: high-risk patients aim for TSH <0.1 mIU/L; low-risk patients can maintain low-normal TSH

• Lenvatinib and sorafenib (multi-kinase inhibitors) - approved for RAI-refractory progressive differentiated TC
• BRAF inhibitors (dabrafenib + trametinib) for BRAF V600E-mutant RAI-refractory DTC

Medullary Thyroid Carcinoma

• Surgery is the mainstay - total thyroidectomy with central neck dissection; lateral neck dissection if lateral nodal disease
• Exclude pheochromocytoma first in all RET mutation carriers before surgery (risk of hypertensive crisis)
• No RAI - MTC does not take up radioiodine
• External beam radiation - palliative for unresectable or metastatic disease
• Vandetanib and cabozantinib - approved kinase inhibitors (targeting RET, VEGFR, EGFR) for advanced/metastatic MTC; provide improved progression-free survival
• Selpercatinib - selective RET inhibitor with high response rates in RET-mutant MTC (2020 FDA approval); pralsetinib is an alternative
• Genetic testing - all patients with MTC should be tested for RET germline mutations; positive results trigger cascade testing of first-degree relatives

Anaplastic Thyroid Carcinoma

• Prognosis is dismal - median survival 3-6 months; nearly 100% mortality (Harrison's, p. 3092)
• RAI is usually ineffective (loss of iodine uptake)
• Multimodal approach:
  • Surgery (if resectable) - debulking may relieve airway obstruction
  • External beam radiation therapy - can be continued if tumors are responsive; often combined with chemotherapy
  • Chemotherapy - anthracyclines (doxorubicin), paclitaxel, cisplatin; generally ineffective as monotherapy
  • BRAF V600E + MEK inhibitor - dabrafenib + trametinib received FDA approval (2018) for BRAF V600E-mutant ATC; response rates ~69%, some durable responses; the first effective regimen for ATC
• Clinical trial enrollment is strongly encouraged

Thyroid Lymphoma

• Most arise in background of Hashimoto's thyroiditis
• Most common type: diffuse large B-cell lymphoma (DLBCL)
• Highly sensitive to external beam radiation when localized
• Surgery should be avoided as initial therapy (may spread localized disease)
• For disseminated disease: systemic lymphoma protocols (R-CHOP)

8. Follow-up

Differentiated Thyroid Cancer

• Sensitive marker for residual or recurrent disease after total thyroidectomy + RAI ablation
• Modern assays with functional sensitivity ~0.1 ng/mL
• Anti-Tg antibodies must be measured simultaneously (interfere with Tg assay)
• Rising Tg or anti-Tg antibodies after initial ablation indicate recurrence

• Performed approximately 6 months after thyroid ablation; more sensitive than whole-body scan for detecting cervical LN recurrence
• Continued at regular intervals based on risk

• Post-treatment WBS after ¹³¹I therapy confirms uptake and identifies metastatic disease
• Stimulated WBS (with TSH elevation) used in high-risk or biochemical-incomplete-response patients

1. Excellent response - 1-4% recurrence risk; follow-up can be relaxed
2. Biochemical incomplete - 50% achieve NED with time or additional therapy
3. Structural incomplete - disease-specific mortality up to 11% (locoregional) to 50% (distant)
4. Indeterminate - 15-20% develop structural disease; continued monitoring

• Years 1-2: Tg every 6-12 months + neck ultrasound at ~6 months then annually
• Years 3-5: Annual Tg + ultrasound (longer intervals if excellent response)
• Long-term: Low-risk patients with undetectable Tg after lobectomy only require TSH + Tg annually

Medullary Thyroid Carcinoma

• Serum calcitonin - primary marker for residual/recurrent disease; measured at 2-3 months post-op, then every 6 months
• CEA - concurrent monitoring; rapid CEA rise without calcitonin rise suggests dedifferentiation
• Neck ultrasound - every 6 months
• CT chest/abdomen, bone scan, MRI liver - for elevated calcitonin or suspected distant metastases
• RET mutation-positive family members - annual calcitonin screening; prophylactic thyroidectomy timing based on ATA risk category

Anaplastic Thyroid Carcinoma

• Imaging (CT neck/chest/abdomen) every 2-3 months given the aggressive disease course
• Follow-up for treatment response and palliative needs

Minimally Invasive Thyroid Surgery: Detailed Notes & Recent Advances

PART 1: MINIMALLY INVASIVE PROCEDURES FOR THYROID SURGERY

Historical Background

1. Cervical minimally invasive - smaller incision in standard location
2. Remote access - incision placed away from the neck entirely

A. Cervical Minimally Invasive Approaches

1. Mini-Open / Small-Incision Thyroidectomy

• Cervicotomy reduced from 6-8 cm to 3-4 cm using standard instruments
• With endoscopic assistance: 1.5-2.5 cm incision
• Terminology: minimally invasive, video-assisted, videoscopic/endoscopic, mini-open
• All demonstrate reasonable feasibility and safety in carefully selected patients

2. Minimally Invasive Video-Assisted Thyroidectomy (MIVAT)

• Introduced by Miccoli (Italy) in 1999
• Incision: 1.5-2 cm suprasternal central cervical incision
• Uses 5 mm 30-degree endoscope + conventional instruments (no gas insufflation needed)
• Patient selection: Thyroid nodule ≤3.5 cm, total gland volume ≤25 mL, no previous neck surgery/irradiation, no thyroiditis
• Advantages: Direct access, no remote flap dissection, preserves cosmetic benefit of small scar
• The endoscope provides excellent magnified visualization of RLN, superior laryngeal nerve, and parathyroid glands (see illustration below)

B. Remote Access Approaches

1. Transaxillary
2. Bilateral Axillo-Breast Approach (BABA)
3. Retroauricular (facelift/hairline)
4. Transoral (TOETVA)

1. Transaxillary Thyroidectomy

• Single 5-6 cm incision in the axilla (or hairline of axilla)
• Gasless technique: subcutaneous tunnel created with long custom retractors
• CO2-assisted variant also used
• Robotic arms + endoscope traverse tunnel from axilla to thyroid
• Da Vinci system provides 3D visualization, 540° of wristed instrumentation, motion scaling

• Conversion to open thyroidectomy: 1 case
• Permanent RLN injury: 1.3%
• Permanent hypoparathyroidism: 1.1%
• Neck hematoma: 0.3%
• Approach-specific complication (arm lymphedema): 1 case, resolved conservatively
• Zero cancer recurrences among 133 patients with histologic malignancy (Sabiston, p. 1529)

• Benign or malignant thyroid disease without ETE or lateral nodal metastases
• Thyroid volume not excessively large (varies by guideline, typically <10 cm in dominant dimension)
• No prior neck surgery
• Patient preference for cosmetic outcome

2. Bilateral Axillo-Breast Approach (BABA)

• Three or four small port incisions: one in each axilla + one or two periareolar incisions
• Creates working space over anterior chest/subcutaneous tissue with CO2 insufflation or gasless retraction
• Advantage: Bilateral thyroid access possible from symmetric ports; symmetric cosmetic incisions hidden in natural creases
• Disadvantage: Larger skin flap area than transaxillary; longer dissection tunnel
• Widely adopted in East Asia; growing use with robotic assistance (robotic BABA)
• Has been used for total thyroidectomy + central neck dissection

3. Retroauricular / Facelift Approach

• Single incision in the retroauricular hairline (facelift incision)
• Tunnel dissection over the sternocleidomastoid to the thyroid
• Robotic assistance (Terris 2012 series, n=15): demonstrated shorter operative time vs transaxillary; amenable to outpatient setting

• Incision hidden in hairline - not visible frontally
• Shorter operative tunnel than transaxillary
• Can be performed ambulatory/outpatient

• Unilateral access; contralateral lobe access more limited
• Risk of greater auricular nerve injury
• Requires familiarity with facelift dissection planes

4. Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA)

• Three port incisions in the oral vestibule (inside the lower lip) - not through oral mucosa
• Uses CO2 gas insufflation
• Central 10 mm trocar + two 5 mm lateral trocars
• Standard laparoscopic instruments or robotic adaptation
• Mental nerve at risk during lateral trocar placement (must stay medial to canine teeth)

• Permanent RLN injury: 0%
• Permanent hypoparathyroidism: 0%
• Neck hematoma requiring open thyroidectomy: 1 case
• Intraoperative conversion: 3 cases
• Transient mental nerve palsy: 0.7% (3 patients)
• Postoperative infection: 0% (Sabiston, p. 1530)

Comparison of Remote Access Approaches

C. Non-Surgical Ablative Procedures (Percutaneous Minimally Invasive)

1. Ethanol (Alcohol) Ablation

• 95-99% dehydrated ethanol injected under US guidance
• Mechanism: coagulative necrosis (cellular dehydration) + ischemic necrosis (small vessel thrombosis)
• Best indication: predominantly cystic thyroid nodules (recurrence after aspiration alone is common)
• Very effective for cystic lesions; less effective for solid nodules
• Low cost; minimal equipment

2. Radiofrequency Ablation (RFA)

• Symptomatic benign nonfunctional thyroid nodules with ATA very low to low suspicion (ACR TI-RADS 1-3) or intermediate suspicion (TI-RADS 4) with benign cytology - two benign biopsies required
• Autonomous functioning nodules (toxic adenoma) with contraindications to RAI or surgery (resolution of hyperthyroidism is less predictable)

• Nodule volume reduction: 65% at 6 months, 77% at 12 months
• Improvement in compressive symptoms and cosmesis
• Better preservation of thyroid function vs surgery
• Better health-related quality of life vs surgery (Sabiston, p. 1530)

• Local recurrence: 2% (RFA), 2% (microwave), 3% (laser)
• Lymph node metastasis: 1% (RFA, lowest)
• No distant metastasis events
• RFA showed superior outcomes in most measures for T1N0M0 PTC
• Not recommended for indeterminate nodules (no histology, risk of tumor progression with incomplete treatment)

3. Microwave Ablation (MWA)

• Electromagnetic field (900-2500 MHz) oscillates polar water molecules to generate heat
• Achieves higher temperatures and larger ablation zones faster than RFA
• Advantage: Less susceptible to heat-sink effect near blood vessels
• Complication rate higher than RFA (13% minor complications in meta-analysis)
• Complete disappearance rate: 71% vs 93% for laser

4. Laser Ablation (LA)

• Single or multiple optical fibers deliver focused laser energy causing thermal coagulation
• Higher complete disappearance rate (93%) than RFA or MWA in meta-analysis
• Local recurrence: 3%
• Minor complication rate 6%

5. High-Intensity Focused Ultrasound (HIFU)

• Ultrasound waves focused to generate heat at target location
• Microbubble formation via cavitation causes hemorrhagic necrosis
• Non-invasive - no needle/probe insertion; entirely external device
• Limited penetration depth; precise targeting required
• Approved in Europe; growing evidence base

PART 2: RECENT ADVANCES IN THYROID SURGERY (2023-2026)

A. Surgical Technique Advances

1. Single-Port (SP) Robotic Thyroidectomy (da Vinci SP System)

• SP Transaxillary - most studied; STAR-RND (Single-port Transaxillary Radical Neck Dissection) and GOSTA-RND approaches allow radical neck dissection with lymph node yields of 25-30, operative times 180-220 minutes
• SP Areolar (SPRA) - periareolar single-port approach
• SP Hairline (retroauricular) - single-port variant
• SP Transoral (TORT) - under development

2. 2025 International Consensus Statement on Remote-Access Surgery

• Minimum surgeon volume requirements for safe practice
• Structured training pathways including cadaveric dissection and proctoring
• Patient eligibility criteria based on disease characteristics
• Oncologic outcomes comparable to open surgery with experienced surgeons
• Improved cosmetic satisfaction
• Development of high-volume centers of excellence recommended

3. 2025 ATA Guidelines Update - Surgical Management Changes

• Lobectomy increasingly preferred for low-risk DTC, expanding beyond prior 2015 thresholds
• Active surveillance recommendations for very low-risk papillary microcarcinoma - avoidance of immediate surgery for select patients
• Detailed guidance on intraoperative parathyroid management (Recommendation 24) - devascularized glands should undergo autotransplantation with frozen section confirmation
• Therapeutic central neck dissection (level VI + upper VII) for clinically involved central nodes (strong recommendation, moderate certainty)

B. Intraoperative Technology Advances

4. Near-Infrared Autofluorescence (NIRAF) for Parathyroid Identification

• Parathyroid tissue emits autofluorescence at 820 nm when excited with near-infrared laser (discovered ~2008; now FDA-approved devices)
• FDA-approved products: PTeye (probe-based; AiBiomed) and Fluobeam-800 (image-based; Fluoptics)
• Sensitivity and accuracy >90% for parathyroid detection
• Limitation: Cannot differentiate healthy vs diseased parathyroid; cannot assess viability; penetration limited to ~5 mm (only useful once gland is exposed)
• Replaces intraoperative frozen section/aspiration for PTH in many centers, potentially reducing operative time
• NOT yet routine but gaining adoption (Fischer's Mastery of Surgery, p. 1172; Schwartz's, p. 1686)

5. Indocyanine Green (ICG) Perfusion Angiography

• IV injection of ICG used with near-infrared camera to generate intraoperative perfusion map of parathyroid glands and their vascular pedicles
• Predicts which parathyroid glands will remain viable after thyroidectomy
• Helps decide which devascularized glands require autotransplantation
• Evidence: reduces permanent hypoparathyroidism rates post-thyroidectomy
• Meta-analysis (PMID 40225464): Image-based NIRAF showed superior sensitivity vs probe-based for parathyroid identification

6. Continuous Intraoperative Neuromonitoring (CIONM)

• Evolution from intermittent to continuous RLN monitoring during thyroidectomy
• Intermittent: periodic direct stimulation and laryngeal palpation
• CIONM: EMG-based continuous system via endotracheal tube electrodes provides real-time warning before impending RLN injury
• Allows the surgeon to pause and reposition before permanent injury occurs
• Current evidence: Multiple studies confirm feasibility; however, no large RCT has proven superiority over intermittent monitoring in reducing injury rates when RLN is routinely visualized (Schwartz's, p. 1686)
• Most useful in reoperative thyroid surgery, large goiters, and thyroid malignancy with ETE

C. Non-Surgical Minimally Invasive Advances (Ablation for Malignancy)

7. Thermal Ablation for Low-Risk Papillary Thyroid Microcarcinoma (PTmC)

• Systematic review and meta-analysis (PMID 37604507, n=36 studies): RFA, MWA, and laser ablation all reliable for T1N0M0 PTC; RFA shows best overall outcomes
• 3-year follow-up RFA meta-analysis for PTmC (PMID 38870871): Low local recurrence (~2%), no distant metastases
• 2026 Ontario Health Technology Assessment (PMID 42311839): Ablative technologies for thyroid nodules formally assessed; supports use for benign disease; evidence for malignancy still maturing

8. Thermal Ablation for Indeterminate Nodules (Bethesda III/IV)

• 2025 systematic review (PMID 40658618): Thermal ablation for indeterminate nodules reduces nodule volume and symptoms
• Major caveat: absence of histology means malignancy cannot be fully excluded; close follow-up mandatory
• Being studied as a bridge or alternative to diagnostic lobectomy in selected Bethesda III cases

9. Quality of Life Data for Benign Disease

• 2025 systematic review (PMID 41213637): Thermal ablation of benign nodules results in significant QoL improvement; comparable or superior to surgical outcomes for symptom control

D. Advances in Management Strategy

10. Active Surveillance for Papillary Thyroid Microcarcinoma

• Japanese Kuma Hospital and Cancer Institute Hospital data (20+ years) established that most PTmC (<1 cm) grow very slowly and rarely progress
• Now incorporated into ATA 2025 guidelines as an accepted alternative to immediate surgery for selected low-risk PTmC
• Criteria: unifocal, intrathyroidal, no LN/distant mets, not adjacent to RLN or trachea, no aggressive histologic features
• A 2026 meta-analysis (PMID 41452620, JAMA Otolaryngol) comparing patient-reported outcomes across treatment strategies (active surveillance, ablation, surgery) for PTmC supports active surveillance as having excellent outcomes with lower treatment burden

11. Active Surveillance for Locoregional Recurrent DTC

• 2026 systematic review and meta-analysis (PMID 41791888, Thyroid): Active surveillance is viable for selected patients with locoregional recurrent DTC, particularly small (<1 cm) cervical nodal metastases with low growth kinetics

12. Lobectomy vs Total Thyroidectomy - Expanding Lobectomy Indications

• Large observational data (SEER, NCDB) confirmed equivalent survival between lobectomy and total thyroidectomy for DTC 1-4 cm without high-risk features
• ATA 2025 guidelines expand lobectomy indications; total thyroidectomy reserved for high-risk disease
• 2025 systematic review (PMID 40915491) on lobectomy vs total thyroidectomy specifically in pediatric DTC shows comparable oncologic outcomes

E. Molecular and Technological Advances

13. Molecular Profiling to Guide Surgery

• ThyroSeq v3, Afirma GSC, ThyGenX/ThyraMIR - gene expression classifiers for indeterminate (Bethesda III/IV) FNA cytology
• Allows "rule out" malignancy → avoidance of diagnostic lobectomy for benign nodules
• Allows "rule in" high-risk mutations (BRAF, TERT, RET fusions) → guide extent of surgery (lobectomy vs total thyroidectomy)
• High-risk molecular profiles (BRAF + TERT co-mutation) favor total thyroidectomy even for smaller tumors

14. Fluorescence-Guided Sentinel Lymph Node Biopsy

• ICG-based sentinel node mapping for thyroid cancer being explored
• May reduce extent of central neck dissection in low-risk PTC by accurately identifying sentinel nodes
• Still investigational; not yet standard of care

15. AI-Assisted Ultrasound and Surgical Navigation

• AI-based ultrasound risk stratification systems increasingly validated
• Computer vision tools for intraoperative RLN recognition being developed
• Augmented reality overlay systems for thyroid surgery orientation under investigation

F. Energy Devices for Hemostasis

16. Advanced Energy Devices

• Harmonic scalpel (ultrasonic coagulation) and LigaSure (vessel sealing) now standard in most thyroid centers
• Reduce operative time, decrease blood loss, and reduce need for suture ligation of inferior thyroid artery branches
• Meta-analyses confirm reduced operative time by ~20-30 minutes and lower drain output compared to traditional cold-knife/suture technique
• Thermal spread is the key safety concern near RLN - energy devices must be kept >3 mm from the nerve

Summary Table: Recent Advances at a Glance

• Sabiston Textbook of Surgery, pp. 1529-1530
• Scott-Brown's Otorhinolaryngology (Vol 3), p. 521
• Schwartz's Principles of Surgery 11E, p. 1686
• Fischer's Mastery of Surgery 8E, p. 1172
• Cummings Otolaryngology, p. 2391
• 2025 International Consensus on Remote-Access Thyroidectomy (PMID 41173534)
• Thermal ablation for T1N0M0 PTC - Meta-analysis (PMID 37604507)
• RFA for PTmC 3-year follow-up (PMID 38870871)
• Patient-reported outcomes in PTmC treatment (PMID 41452620)
• Single-port robotic thyroidectomy review 2025 (PMC12799353)